Dr. Pedram Argani, MD is a Professor of Pathology and Oncology at the Johns Hopkins University School of Medicine, Baltimore, Maryland. He described the Xp11 translocation renal cell carcinomas and the t(6;11) renal cell carcinomas in 2001. The Xp11 translocation renal cell carcinomas were accepted as distinctive entity by the 2004 World Health Organization (WHO) classification of renal neoplasia, while the t(6;11) renal cell carcinomas would be recognized in the upcoming 2015 WHO renal tumor classification. Following Dr. Argani’s initial discovery of these neoplasms, he has performed studies to delineate the clinical behavior of these neoplasms, as well as their responses to therapy.

He has developed immunohistochemical and fluorescence in situ hybridization (FISH) assays which can be used to identify these neoplasms in routine pathology material. He has identified therapeutic targets in these neoplasms, such as C-met overexpression and mTOR pathway activation. Through his pathology consultation service, he likely has the world’s largest collection of these neoplasms, and has created tissue microarrays harboring many of these neoplasms to expedite further molecular characterization. Dr. Argani’s laboratory is actively searching for therapeutic targets in these neoplasms which will improve patient outcome.